However, as previous PET imaging studies have reported reduced mGluR5 levels in the HPC of AD patients (Table 2), further clinical investigations are warranted to determine the long-term efficacy and optimal timing of mGluR5-targeted therapies in humans. Here, GRM5 is linked to Alzheimer disease.